The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Oxaliplatin and capecitabine initially concomitant to radiotherapy then administered in the resting period in high-risk locally advanced rectal cancer.
Pei-Rong Ding
No relevant relationships to disclose
Yuan-Hong Gao
No relevant relationships to disclose
Xin An
No relevant relationships to disclose
Gong Chen
No relevant relationships to disclose
Feng-Hua Wang
No relevant relationships to disclose
Mu-Yan Cai
No relevant relationships to disclose
Zhi-Fan Zeng
No relevant relationships to disclose
Ling-Heng Kong
No relevant relationships to disclose
Jun-Zhong Lin
No relevant relationships to disclose
Xiaojun Wu
No relevant relationships to disclose
Zhen-Hai Lu
No relevant relationships to disclose
Li-Ren Li
No relevant relationships to disclose
De-Sen Wan
No relevant relationships to disclose
Zhi-Zhong Pan
No relevant relationships to disclose